Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 MPO Provides Further Discrimination in Survival When Combined With LVEF or NT-proBNP
Kaplan-Meier cumulative survival curves for myocardial infarction patients with above- and below-median myeloperoxidase (MPO) over a 5-year follow-up in combination with (A) above- and below-median left ventricular ejection fraction (LVEF) (p < 0.0001) and (B) above- and below-median plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels (p < 0.0001). Differences in survival between patient groups are indicated, except for between groups A and B where there was no significant difference. Medians: MPO = 55 ng/ml; protein carbonyls = 48 pmol/mg; LVEF = 49%; NT-proBNP = 110 pmol/l.
|
